4.5 Article

Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson et al.

NATURE MEDICINE (2015)

Article Medicine, General & Internal

Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia

Steven P. Treon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Hematology

Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop

Roger G. Owen et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Article Medicine, General & Internal

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

Michael L. Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Medicine, General & Internal

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Article Immunology

Bruton's tyrosine kinase is required for TLR-induced IL-10 production

Nathan W. Schmidt et al.

JOURNAL OF IMMUNOLOGY (2006)

Review Immunology

Regulation of B-cell fate by antigen-receptor signals

H Niiro et al.

NATURE REVIEWS IMMUNOLOGY (2002)